Cargando…
Multi-nanolayer drug delivery using radiofrequency plasma technology
BACKGROUND: It may be impossible to perform cancer surgery with free margins in the presence of an unresectable structure. Local drug treatment after surgery has been proposed to increase the rate of tumor control. METHODS: Multi-nanolayers (10-330 nm) were generated by a low-pressure (375mTorr) ind...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302375/ https://www.ncbi.nlm.nih.gov/pubmed/32552705 http://dx.doi.org/10.1186/s12885-020-06989-w |
_version_ | 1783547832945344512 |
---|---|
author | Al Dybiat, Iman Baitukha, Alibi Pimpie, Cynthia Kaci, Rachid Pocard, Marc Arefi Khonsari, Farzaneh Mirshahi, Massoud |
author_facet | Al Dybiat, Iman Baitukha, Alibi Pimpie, Cynthia Kaci, Rachid Pocard, Marc Arefi Khonsari, Farzaneh Mirshahi, Massoud |
author_sort | Al Dybiat, Iman |
collection | PubMed |
description | BACKGROUND: It may be impossible to perform cancer surgery with free margins in the presence of an unresectable structure. Local drug treatment after surgery has been proposed to increase the rate of tumor control. METHODS: Multi-nanolayers (10-330 nm) were generated by a low-pressure (375mTorr) inductively coupled plasma (13.56 MHz) reactor for anticancer drug delivery by the deposition of polycaprolactone-polyethylene glycol multistack barrier on the collagen membrane (100 μm thickness). Carboplatin (300 μg/cm(2)) was used for the in vitro and in vivo investigations. Energy-dispersive X-ray spectroscopy (15 keV), scanning electron microscopy and inductively coupled plasma mass spectrometry were used to detect the presence of carboplatin in the nanolayer, the tumor sample and the culture medium. Preclinical studies were performed on ovarian (OVCAR-3NIH) and colon (CT26) cancer cell lines as xenografts (45 days) and allografts (23 days) in Swiss-nude (n = 6) and immunocompetent BALB/cByJ mice (n = 24), respectively. RESULTS: The loading of carboplatin or other drugs between the nanofilm on the collagen membrane did not modify the mesh complex architecture or the drug properties. Drugs were detectable on the membrane for more than 2 weeks in the in vitro analysis and more than 10 days in the in vivo analysis. Cytotoxic mesh decreased cell adherence (down 5.42-fold) and induced cancer cell destruction (up to 7.87-fold). Implantation of the mesh on the mouse tumor nodule modified the cell architecture and decreased the tumor size (50.26%) compared to the control by inducing cell apoptosis. CONCLUSION: Plasma technology allows a mesh to be built with multi-nanolayer anticancer drug delivery on collagen membranes. |
format | Online Article Text |
id | pubmed-7302375 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-73023752020-06-19 Multi-nanolayer drug delivery using radiofrequency plasma technology Al Dybiat, Iman Baitukha, Alibi Pimpie, Cynthia Kaci, Rachid Pocard, Marc Arefi Khonsari, Farzaneh Mirshahi, Massoud BMC Cancer Research Article BACKGROUND: It may be impossible to perform cancer surgery with free margins in the presence of an unresectable structure. Local drug treatment after surgery has been proposed to increase the rate of tumor control. METHODS: Multi-nanolayers (10-330 nm) were generated by a low-pressure (375mTorr) inductively coupled plasma (13.56 MHz) reactor for anticancer drug delivery by the deposition of polycaprolactone-polyethylene glycol multistack barrier on the collagen membrane (100 μm thickness). Carboplatin (300 μg/cm(2)) was used for the in vitro and in vivo investigations. Energy-dispersive X-ray spectroscopy (15 keV), scanning electron microscopy and inductively coupled plasma mass spectrometry were used to detect the presence of carboplatin in the nanolayer, the tumor sample and the culture medium. Preclinical studies were performed on ovarian (OVCAR-3NIH) and colon (CT26) cancer cell lines as xenografts (45 days) and allografts (23 days) in Swiss-nude (n = 6) and immunocompetent BALB/cByJ mice (n = 24), respectively. RESULTS: The loading of carboplatin or other drugs between the nanofilm on the collagen membrane did not modify the mesh complex architecture or the drug properties. Drugs were detectable on the membrane for more than 2 weeks in the in vitro analysis and more than 10 days in the in vivo analysis. Cytotoxic mesh decreased cell adherence (down 5.42-fold) and induced cancer cell destruction (up to 7.87-fold). Implantation of the mesh on the mouse tumor nodule modified the cell architecture and decreased the tumor size (50.26%) compared to the control by inducing cell apoptosis. CONCLUSION: Plasma technology allows a mesh to be built with multi-nanolayer anticancer drug delivery on collagen membranes. BioMed Central 2020-06-17 /pmc/articles/PMC7302375/ /pubmed/32552705 http://dx.doi.org/10.1186/s12885-020-06989-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Al Dybiat, Iman Baitukha, Alibi Pimpie, Cynthia Kaci, Rachid Pocard, Marc Arefi Khonsari, Farzaneh Mirshahi, Massoud Multi-nanolayer drug delivery using radiofrequency plasma technology |
title | Multi-nanolayer drug delivery using radiofrequency plasma technology |
title_full | Multi-nanolayer drug delivery using radiofrequency plasma technology |
title_fullStr | Multi-nanolayer drug delivery using radiofrequency plasma technology |
title_full_unstemmed | Multi-nanolayer drug delivery using radiofrequency plasma technology |
title_short | Multi-nanolayer drug delivery using radiofrequency plasma technology |
title_sort | multi-nanolayer drug delivery using radiofrequency plasma technology |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7302375/ https://www.ncbi.nlm.nih.gov/pubmed/32552705 http://dx.doi.org/10.1186/s12885-020-06989-w |
work_keys_str_mv | AT aldybiatiman multinanolayerdrugdeliveryusingradiofrequencyplasmatechnology AT baitukhaalibi multinanolayerdrugdeliveryusingradiofrequencyplasmatechnology AT pimpiecynthia multinanolayerdrugdeliveryusingradiofrequencyplasmatechnology AT kacirachid multinanolayerdrugdeliveryusingradiofrequencyplasmatechnology AT pocardmarc multinanolayerdrugdeliveryusingradiofrequencyplasmatechnology AT arefikhonsarifarzaneh multinanolayerdrugdeliveryusingradiofrequencyplasmatechnology AT mirshahimassoud multinanolayerdrugdeliveryusingradiofrequencyplasmatechnology |